How Many People Work at United Therapeutics? Headcount and Employee Trends

• United Therapeutics (NASDAQ: UTHR), headquartered in Silver Spring, Maryland, specializes in developing and commercializing innovative therapies for pulmonary arterial hypertension (PAH) and other serious conditions, achieving a record revenue of $3.18 billion in 2025, marking an 11% growth from the previous year.
• In 2025, the company announced plans to file for regulatory approval of its new drug 'Tresmi' for PAH and interstitial lung disease (ILD), alongside enhancements to its Tyvaso DPI platform, including new dosing options and a proprietary soft mist inhaler, 'Trismi', aimed at reducing inhaler-related cough by up to 90%.
• United Therapeutics is currently in discussions with three pharmaceutical companies regarding its AI-enabled digital lung model for in silico Phase III trials, indicating a strategic focus on leveraging technology in drug development.
• The ideal buyer for United Therapeutics' products includes healthcare providers and institutions managing patients with PAH and ILD, as the company addresses critical treatment gaps with innovative therapies that enhance patient outcomes and compliance.

United Therapeutics operates with a streamlined departmental structure, consisting of a single department: Finance, which employs 1 individual. This indicates a highly centralized approach to financial management within the organization. The absence of additional departments suggests a focused operational strategy, potentially reflecting a niche market or specialized business model.

The company is headquartered in Silver Spring, Maryland, with no additional locations reported. The workforce is concentrated in this singular location, indicating a centralized operational model. The designation of 'Other' for location suggests a minimal geographic distribution, reinforcing the notion of a tightly-knit organizational framework.